Status:
COMPLETED
Treatment After Palbociclib-containing Regimens
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.
Eligibility Criteria
Inclusion
- woman, age \> 18 years old
- Diagnosed with HR+/HER2- Metastatic Breast Cancer
- Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy
- Complete medical history was available
Exclusion
- 1\. Medical history was incomplete
Key Trial Info
Start Date :
August 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04517318
Start Date
August 15 2017
End Date
July 15 2021
Last Update
August 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032